Drug class
HIV-1 fusion inhibitor; gp41 HR1 domain-binding peptide
Mechanism of action
Binds the heptad-repeat 1 (HR1) region of HIV-1 gp41, preventing the conformational changes required for fusion of the viral envelope with the host-cell membrane and blocking viral entry.
General use cases
- Treatment of HIV-1 infection in heavily treatment-experienced adults and paediatric patients aged 6 years and older in combination with other antiretroviral agents when resistance or intolerance limits other options; subcutaneous administration only
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
